Associated Papers
Pleiotropic tumor suppressive functions of PTEN missense mutations during gliomagenesis.
Jun HJ et al.
Iscience, 2024
STING activation increases the efficiency of temozolomide in PTEN harbouring glioblastoma cells.
Yildirim Z et al.
Turkish Journal of Medical Sciences, 2024
Source, co-occurrence, and prognostic value of PTEN mutations or loss in colorectal cancer.
Serebriiskii IG et al.
Npj Genomic Medicine, 2023
Molecular dynamic simulation and functional analysis of pathogenic PTEN mutations in glioblastoma.
Cetintas VB et al.
Journal of Biomolecular Structure & Dynamics, 2023
Mechanism of activation and the rewired network: New drug design concepts.
Nussinov R et al.
Medicinal Research Reviews, 2022
Integrating thousands of PTEN variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers.
Matreyek KA et al.
Genome Medicine, 2021
A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database.
Pappula AL et al.
Cancers, 2021
Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes.
Moukarzel LA et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2021
Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition.
Nussinov R et al.
Molecular Cancer Research : Mcr, 2021
Analyzing aggregation propensities of clinically relevant PTEN mutants: a new culprit in pathogenesis of cancer and other PTENopathies.
Palumbo E et al.
Journal of Biomolecular Structure & Dynamics, 2020
Structural Mechanisms of PTEN Regulation.
Masson GR et al.
Cold Spring Harbor Perspectives in Medicine, 2020
The Impact of Genetic Variants on PTEN Molecular Functions and Cellular Phenotypes.
Hasle N et al.
Cold Spring Harbor Perspectives in Medicine, 2019
65 YEARS OF THE DOUBLE HELIX: The advancements of gene editing and potential application to hereditary cancer.
Tan ZY et al.
Endocrine-related Cancer, 2018
EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer.
Oldrini B et al.
Nature Communications, 2017
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.
Milella M et al.
Scientific Reports, 2017
Correction of PTEN mutations in glioblastoma cell lines via AAV-mediated gene editing.
Hill VK et al.
Plos One, 2017
Opening the conformation is a master switch for the dual localization and phosphatase activity of PTEN.
Nguyen HN et al.
Scientific Reports, 2015
A new class of cancer-associated PTEN mutations defined by membrane translocation defects.
Nguyen HN et al.
Oncogene, 2015
Engineering PTEN function: membrane association and activity.
Yang JM et al.
Methods (san Diego, Calif.), 2015
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.
Brannon AR et al.
Genome Biology, 2014
A new insight into structural and functional impact of single-nucleotide polymorphisms in PTEN gene.
George Priya Doss C et al.
Cell Biochemistry and Biophysics, 2013
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
CanDrA: cancer-specific driver missense mutation annotation with optimized features.
Mao Y et al.
Plos One, 2013
PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity.
Tibarewal P et al.
Science Signaling, 2012
Predicting the functional impact of protein mutations: application to cancer genomics.
Reva B et al.
Nucleic Acids Research, 2011
Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model.
Endersby R et al.
Cancer Research, 2011
PTEN mutations in malignant gliomas and their relation with meningeal gliomatosis.
Izumoto S et al.
Journal of Neuro-oncology, 2001
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
Teng DH et al.
Cancer Research, 1997
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
Steck PA et al.
Nature Genetics, 1997